Thermo Fisher Scientific Inc.

Equities

TMO

US8835561023

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 12:58:20 2025-01-22 pm EST			5-day change	1st Jan Change
576.49 ^USD	+0.60%		+4.76%	+11.05%

Jan. 21	Stephens Adjusts Price Target on Thermo Fisher Scientific to $640 From $670	MT
Jan. 15	US Government to Restrict Biotechnology Equipment Exports to China	MT

Tranche Update on Thermo Fisher Scientific Inc.'s Equity Buyback Plan announced on November 14, 2023.

November 01, 2024 at 11:36 am EDT

From June 30, 2024 to September 28, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 5,523,139 shares, representing 1.43% for $3,000 million under the buyback announced on November 14, 2023.

Latest news about Thermo Fisher Scientific Inc.

Stephens Adjusts Price Target on Thermo Fisher Scientific to $640 From $670	Jan. 21	MT
US Government to Restrict Biotechnology Equipment Exports to China	Jan. 15	MT
Goldman Sachs Adjusts Thermo Fisher Scientific Price Target to $630 From $655	Jan. 15	MT
Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies	Jan. 15	CI
Thermo Fisher Scientific Looks for M&A	Jan. 14	CI
Thermo Fisher Scientific Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 08:15 AM	Jan. 14
Morgan Stanley Adjusts Price Target on Thermo Fisher Scientific to $647 From $670	Jan. 10	MT
Bernstein Upgrades Thermo Fisher Scientific to Outperform From Market Perform, Raises Price Target to $630 From $620	Jan. 10	MT
Hiring highs trigger Wall Street woes: No cuts on the horizon	Jan. 10
Bernstein Upgrades Thermo Fisher Scientific to Outperform From Market Perform, Adjusts Price Target to $630 From $620	Jan. 10	MT
Analyst recommendations: AMD, McDonald's, Nike, Ross Stores, Snowflake...	Jan. 10
Thermo Fisher Scientific Says Olink Platform Chosen by UK Proteomics Project	Jan. 10	MT
UK Biobank Pharma Proteomics Project Selects Thermo Fisher Scientific's Olink Platform for World's Largest Human Proteome Study	Jan. 09	CI
Wolfe Research Adjusts Thermo Fisher Scientific's Price Target to $650 From $680, Maintains Outperform Rating	Jan. 06	MT
Argus Adjusts Thermo Fisher Scientific's Price Target to $620 From $665	Jan. 06	MT
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $585 From $620	Jan. 02	MT
Scotiabank Initiates Thermo Fisher Scientific at Sector Perform With $605 Price Target	Dec. 23	MT
RBC Trims Price Target on Thermo Fisher Scientific to $692 From $711, Keeps Outperform Rating	Dec. 20	MT
RBC Trims Price Target on Thermo Fisher Scientific to $692 From $711, Keeps Outperform Rating	Dec. 20	MT
Deutsche Bank Adjusts Thermo Fisher Scientific Price Target to $605 From $630	Dec. 18	MT
4basebio PLC Announces Appointment of Alan Malus as Independent Non-Executive Director	Dec. 17	CI
Jefferies Adjusts Price Target on Thermo Fisher Scientific to $650 From $655	Dec. 12	MT
RBC Trims Price Target on Thermo Fisher Scientific to $711 From $718, Keeps Outperform Rating	Dec. 09	MT
Thermo Fisher Scientific Insider Sold Shares Worth $10,624,559, According to a Recent SEC Filing	Dec. 04	MT
Thermo Fisher Scientific Launches CTS? Detachable Dynabeads? CD4 and CTS Detachable Dynabeads CD8 to Enhance Cell Therapy Development and Production	Dec. 04	CI

Chart Thermo Fisher Scientific Inc.

Duration

Period

TMO: Dynamic Chart

Company Profile

Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (70%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - diagnostics equipment and products (15.3%); - scientific analysis equipments (14.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc. Net sales break down by source of income into products sales (78.5%) and services (21.5%). Net sales break down geographically as follows: North America (53%), Europe (25.7%), Asia-Pacific (18.1%) and others (3.2%).

Employees

122,000

Sector

Advanced Medical Equipment & Technology

Calendar

2025-01-30 - Q4 2024 Earnings Release

More about the company